Accelerate Diagnostics (NASDAQ:AXDX) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

AXDX has been the subject of a number of other research reports. Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday, January 15th. ValuEngine raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BTIG Research lowered shares of Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 13th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. Accelerate Diagnostics currently has an average rating of “Hold” and an average price target of $33.00.

Accelerate Diagnostics (NASDAQ AXDX) opened at $23.25 on Tuesday. The firm has a market cap of $1,290.00, a price-to-earnings ratio of -19.38 and a beta of 2.19. Accelerate Diagnostics has a 52-week low of $16.75 and a 52-week high of $30.45.

In other news, Director Jack W. Schuler bought 5,500 shares of the business’s stock in a transaction on Friday, November 17th. The stock was purchased at an average price of $22.00 per share, with a total value of $121,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 50.00% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. raised its position in shares of Accelerate Diagnostics by 7.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 117,236 shares of the medical research company’s stock valued at $3,207,000 after buying an additional 7,930 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Accelerate Diagnostics by 13.0% during the second quarter. The Manufacturers Life Insurance Company now owns 21,125 shares of the medical research company’s stock valued at $578,000 after buying an additional 2,425 shares during the last quarter. Artemis Investment Management LLP acquired a new position in shares of Accelerate Diagnostics during the third quarter valued at about $2,245,000. Wells Fargo & Company MN raised its position in shares of Accelerate Diagnostics by 21.2% during the second quarter. Wells Fargo & Company MN now owns 73,328 shares of the medical research company’s stock valued at $2,005,000 after buying an additional 12,840 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Accelerate Diagnostics during the third quarter valued at about $2,053,000. 47.56% of the stock is owned by institutional investors and hedge funds.

WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2018/02/15/bidaskclub-downgrades-accelerate-diagnostics-axdx-to-hold.html.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.